News Release

INDIANAPOLIS, Sept. 9, 2014 /PRNewswire/ -- Fifty abstracts designed to advance knowledge in diabetes science will be presented Sept. 15-19 by Eli Lilly and Company (NYSE: LLY) at the 50^thEuropean Association for the Study of Diabetes (EASD) Annual Meeting. Notably, the company is highlighting two of its late-stage products: basal insulin peglispro and once-weekly dulaglutide. Twenty-eight of the abstracts will be presented as part of the Boehringer Ingelheim-Lilly Diabetes Alliance. EASD will take place in Vienna, Austria.

"Lilly's legacy of diabetes research continues today, and we are committed to advancing knowledge among healthcare professionals in the diabetes community," said Gwen Krivi, Ph.D., vice president, Lilly Diabetes product development. "With 382 million people worldwide affected by diabetes, our goal is to drive forward research on new and existing treatments that may provide patients with new options."

Among the data being presented at EASD are:

Dulaglutide: Among the abstracts showcased at the meeting, Lilly will give three oral presentations for once-weekly dulaglutide, an investigational long-acting glucagon-like peptide-1 (GLP-1) receptor agonist being studied for the treatment of type 2 diabetes. Details for these and other presentations are as follows:

• Tuesday, September 16, 2:15 - 3:15 p.m. CEST, Poster Presentation
  • Pharmacokinetics of once weekly dulaglutide in special populations (Lead author: C. Loghin) [Presentation 880]
• Tuesday, September 16, 3:30 - 5:00 p.m. CEST, Oral Presentation
  • Efficacy and safety of once weekly dulaglutide versus insulin glargine in combination with metformin and glimepiride in type 2 diabetes patients (AWARD-2) (Lead author: F. Giorgino) [Presentation 38]
  • Efficacy and safety of once weekly dulaglutide versus once daily liraglutide in type 2 diabetes (AWARD-6) (Lead author: S. Tofe Povedano) [Presentation 40]
  • Better glycemic control and less weight gain with once weekly dulaglutide versus bedtime insulin glargine, both combined with thrice daily lispro, in type 2 diabetes (AWARD-4) (Lead author: J. Jendle) [Presentation 42]
• Wednesday, September 17, 1:00 - 2:00 p.m. CEST, Poster Presentation
  • The 2 week fasting glucose as a predictor of response to once weekly dulaglutide 1.5 mg (Lead author: T. Forst) [Presentation 827]
• Wednesday, September 17, 2:15 - 3:15 p.m. CEST, Poster Presentation
  • A network meta-analysis to compare once weekly dulaglutide versus other GLP-1 receptor agonists in patients with type 2 diabetes (Lead author: A. Padhiar) [Presentation 839]
• Thursday, September 18, 1:00 - 2:00 p.m. CEST, Poster Presentation
  • Patient-reported outcomes with once weekly dulaglutide 1.5 mg versus once daily liraglutide 1.8 mg (AWARD-6) (Lead author: K.S. Boye) [Presentation 907]
• Thursday, September 18, 2:15 - 3:15 p.m. CEST, Poster Presentation
  • Pharmacokinetics of once weekly dulaglutide in patients with type 2 diabetes mellitus (Lead author: A. de la Pena) [Presentation 857]

Basal Insulin Peglispro: Lilly will present three abstracts with pre-clinical and human mechanism of action data for its investigational basal insulin peglispro. Details for the presentations are as follows:

• Tuesday, September 16, 2:15 - 3:15 p.m. CEST, General Poster Session
  • Pharmacokinetics and elimination of basal insulin peglispro (BIL) versus PEG-only in rats following a single IV or SC dose (Lead author: M. Knadler) [Presentation 938]
• Thursday, September 18, 1:00 - 2:00 p.m. CEST, General Poster Session
  • A single dose pharmacokinetic study of basal insulin peglispro in subjects with hepatic impairment (Lead author: S.L. Choi) [Presentation 957]
• Thursday, September 18, 2:15 - 3:15 p.m. CEST, General Poster Session
  • Binding kinetics, internalisation and localisation of long-acting basal insulin peglispro (BIL) and Insulin receptor in cells (Lead author: V.V. Kiselyov) [Presentation 971]

About Diabetes
An estimated 382 million people worldwide have type 1 and type 2 diabetes. Type 2 diabetes is the most common type, accounting for an estimated 85 to 95 percent of all diabetes cases. Diabetes is a chronic disease that occurs when the body either does not properly produce, or use, the hormone insulin.[1] 

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a broad and growing product portfolio and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.com.

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels.

P-LLY

This press release contains forward-looking statements about two investigational compounds, dulaglutide and basal insulin peglispro LY2605541, which are currently in development for the treatment of diabetes. It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. There is no guarantee that future study results and patient experience will be consistent with study findings to date or that dulaglutide and/or basal insulin peglispro LY2605541 will receive required regulatory approvals or prove to be commercially successful. For further discussion of these and other risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

[1] International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels, Belgium: International Diabetes Federation, 2013. http://www.idf.org/diabetesatlas.

Refer to:
Candace Johnson (for dulaglutide inquiries), +1-317-755-9143, johnson_candace_a@lilly.com
Molly McCully (for basal insulin peglispro inquiries), +1-317-478-5423, mccully_molly@lilly.com

Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO

SOURCE Eli Lilly and Company